Unidad de Investigación Clínica en Inmunoterapia del Cáncer H12O-CNIO

Inicio | Investigación e innovación | Programas Científicos | Programa de Investigación Clínica | Unidad de Investigación Clínica en Inmunoterapia del Cáncer H12O-CNIO

Luis Álvarez-Vallina
Luis Álvarez-Vallina Jefe de Unidad de Investigación Clínica
T +34 (+34) 917 328 000 (Ext 2950)

Investigadores Científicos

  • Belén Blanco
  • Anais Jiménez

Becarios Post-doctorales

  • Rodrigo Lázaro
  • Ángel Ramírez
  • Antonio Tapia
  • Ivana Zagorac

Becarios Pre-Doctorales

  • Francisco Javier Arroyo
  • Laura Díez
  • Carmen Domínguez
  • Eva García
  • Marina Gómez
  • Susana Luengo
  • Laura Rubio
  • Alejandro Segura
  • Miriam Velasco

Técnicos de Laboratorio

  • María de la Yedra Pacheco

Our Unit focuses on understanding the molecular and cellular mechanisms of cancer immune escape in order to design next-generation cancer immunotherapies. For example, we have developed a novel strategy based on the secretion of bispecific T cell-engaging antibodies by engineered human T (STAb-T) cells, which has been shown to be effective in solid and haematological malignancies and is currently being tested in clinical trials. The Cancer Immunotherapy Clinical Research Unit has several research areas of interest: 1) reactivation of tumour-specific endogenous T cells; 2) development of tumour-reactive “artificial” T cells; and 3) development of multi-targeting approaches recognising extra- and intracellular tumour antigens. Our group also has a strong interest in the generation of multi-specific antibodies and the use of engineered mRNA-based delivery systems. Finally, our Unit is firmly committed to introducing new immuno-oncology drugs and adoptive cell therapies in the clinic, to provide high-quality personalised treatments.